Dane Cheasley

305 Grattan Street
Parkville, VIC 3000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.

Journal: International journal of molecular sciences

Published: December 13, 2025

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile.

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile.

Journal: The Journal of pathology

Published: October 28, 2025

A scalable, multi-resolution consensus clustering approach for prioritizing robust signals from high-throughput screens.

A scalable, multi-resolution consensus clustering approach for prioritizing robust signals from high-throughput screens.

Journal: Briefings in bioinformatics

Published: July 17, 2025

Breast cancers arising in high mammographic density tissue harbor tumor-promoting immune profiles.

Breast cancers arising in high mammographic density tissue harbor tumor-promoting immune profiles.

Journal: NPJ breast cancer

Published: February 10, 2025

Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma.

Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: June 24, 2024

Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing.

Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing.

Journal: NPJ genomic medicine

Published: April 22, 2024

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma.

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma.

Journal: Scientific data

Published: March 18, 2024

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 24, 2022

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.

Journal: NPJ precision oncology

Published: December 29, 2021

Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer.

Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer.

Journal: Cancers

Published: September 28, 2021

Primary mucinous ovarian neoplasms rarely show germ cell histogenesis.

Primary mucinous ovarian neoplasms rarely show germ cell histogenesis.

Journal: Histopathology

Published: November 05, 2020

Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study.

Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study.

Journal: NPJ breast cancer

Published: October 31, 2020

Showing 1-12 of 28

Last Updated: 09/26/2026